{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:51:09Z","timestamp":1792741869040,"version":"4.5.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>On June 30, 2009, the United States Food and Drug Administration (FDA) approved ferumoxytol (Feraheme\u2122 injection, AMAG Pharmaceuticals), an iron\u2010containing product for intravenous (IV) administration, for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). The safety and efficacy of ferumoxytol were assessed in three randomized, open\u2010label, controlled clinical trials. Two trials evaluated patients with nondialysis dependent CKD and a third trial assessed patients undergoing hemodialysis. Randomization was either to ferumoxytol or oral iron. Ferumoxytol was administered as two 510 mg IV injections, separated by 3\u20138 days. Oral iron, Ferro\u2010Sequels\u00ae, was administered at a dose of 100 mg twice daily for 21 days. In all three clinical trials, ferumoxytol administration increased the mean blood hemoglobin (Hgb) concentrations by \u223c1.0 g\/dL over the 35 day period, a mean increase that was greater than what was observed in patients receiving oral iron. Patients receiving ferumoxytol also had increases in blood transferrin saturation (TSAT) and ferritin values. For the proposed ferumoxytol dosing regimen, 4.9% of patients had serum ferritin \u2265800 ng\/mL and TSAT \u226550% post\u2010treatment. The most important ferumoxytol safety concerns were hypersensitivity reactions and\/or hypotension. Anaphylaxis or anaphylactoid reactions were reported in 0.2% of subjects, and other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria, or wheezing) were reported in 3.7%. Hypotension was observed in 1.9%, including three patients with serious hypotensive reactions. Ferumoxytol administration may transiently affect the diagnostic ability of magnetic resonance imaging and the drug label provides further information regarding this effect. Am. J. Hematol. 2010. Published 2010 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21656","type":"journal-article","created":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T10:43:06Z","timestamp":1263984186000},"page":"315-319","source":"Crossref","is-referenced-by-count":394,"title":["FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease"],"prefix":"10.1002","volume":"85","author":[{"given":"Min","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwaine","family":"Rieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,21]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00365.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2008.12.008"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0913"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80135-1"},{"issue":"3","key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.ajkd.2008.11.017","article-title":"K\/DOQI clinical practice guidelines and clinical practice recommendations for anemia of chronic kidney disease, 2006","volume":"47","author":"National Kidney Foundation","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01490506"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69018.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e328324b672"},{"key":"e_1_2_1_10_2","first-page":"184","article-title":"IV iron use in patients with higher serum ferritin: Case study on anemia in kidney disease","volume":"35","author":"Larson K","year":"2008","journal-title":"Nephrol Nurs J"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69061.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/snep.2002.35972"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.05.033"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2008.09.010"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.femsim.2004.11.010"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2002.0320s1042.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2008.811"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00648.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002422"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.09.006"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02130.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.08.001"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02840608"},{"key":"e_1_2_1_24_2","first-page":"367","article-title":"Wood L oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose","volume":"15","author":"Jacobs P","year":"1984","journal-title":"J Med"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90105-1"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000034200.82278.DC"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69079.x"},{"key":"e_1_2_1_28_2","first-page":"571","article-title":"Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients","volume":"30","author":"Folkert VW","year":"2003","journal-title":"Nephrol Nurs J"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186956"},{"key":"e_1_2_1_30_2","first-page":"201","article-title":"The use of epoetin beta in anemic predialysis patients with chronic renal failure","volume":"44","author":"Koch KM","year":"1995","journal-title":"Clin Nephrol"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90546-6"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70104-6"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0405-y"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002779"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21656","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T22:20:26Z","timestamp":1700605226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,21]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1002\/ajh.21656"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21656","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,21]]}}}